Tumor-Targeting CD137/HER2 Bispecifics Exhibit Differentiation Over Anti-CD137 Monoclonal Antibodies and Possess Desired Drug-Like Properties
BOSTON, MA, USA I November 06, 2015 I Pieris Pharmaceuticals, Inc. (PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, announced today the presentation of new preclinical data from its lead immuno-oncology program demonstrating that its Anticalin-based CD137/HER2 bispecific PRS-343 drug candidates stimulate tumor-targeted immune responses distinct from conventional anti-CD137 monoclonal antibodies and possess desirable drug-like properties.
Pieris’ PRS-343 bispecifics, which simultaneously target the inducible T-cell costimulatory receptor CD137 and the HER2 tumor antigen, are designed to promote CD137 clustering by bridging T cells with HER2-positive tumor cells, thereby providing a selective activation signal to tumor-specific T cells. They are in development for immunotherapy of HER2-positive cancers.
To be presented today at a poster session during the 2015 Annual Meeting for the Society for Immunotherapy of Cancer (SITC), the data demonstrate that PRS-343 drug candidates drive tumor-targeted T cell activation on multiple HER2 high-expressing tumor cell lines but not on HER2 low-expressing tumor cell lines, confirming the requirement of tumor-expressed HER2 binding to trigger the CD137-mediated anti-tumor immune response. In contrast, a reference anti-CD137 monoclonal antibody was demonstrated to activate T cells independent of tumor cell HER2 expression.
In additional presented studies, the PRS-343 drug candidates exhibited desirable drug-like properties with respect to stability, pharmacokinetic, and immunogenicity profiles. These included retaining full activity after four weeks at 40°C, as well as having both a predicted serum half-life equivalent to a monoclonal antibody and low immunogenicity risk.
A copy of the poster can be viewed and downloaded by clicking
http://c.eqcdn.com/pierisag/files/posters/151102+November+Poster+postFinal+SITI.pdf.
Pieris Senior VP and Chief Development Officer, Louis Matis, M.D, commented, “CD137 is a highly promising target for cancer immunotherapy. However, conventional CD137-targeting antibodies lack tumor-selective activity, which may increase the risk of systemic toxicity. In contrast, by promoting CD137-induced immune activation that is localized to sites of HER2-positive tumor involvement, Pieris’ bispecifics have the potential to enhance the therapeutic window for the target, affording greater safety and efficacy. We are actively advancing this program toward clinical studies as a top priority.”
About Pieris Pharmaceuticals:
Pieris is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat severe asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin®, Anticalins® are registered trademarks of Pieris. For more information visit www.pieris.com.
SOURCE: Pieris Pharmaceuticals
Post Views: 218
Tumor-Targeting CD137/HER2 Bispecifics Exhibit Differentiation Over Anti-CD137 Monoclonal Antibodies and Possess Desired Drug-Like Properties
BOSTON, MA, USA I November 06, 2015 I Pieris Pharmaceuticals, Inc. (PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, announced today the presentation of new preclinical data from its lead immuno-oncology program demonstrating that its Anticalin-based CD137/HER2 bispecific PRS-343 drug candidates stimulate tumor-targeted immune responses distinct from conventional anti-CD137 monoclonal antibodies and possess desirable drug-like properties.
Pieris’ PRS-343 bispecifics, which simultaneously target the inducible T-cell costimulatory receptor CD137 and the HER2 tumor antigen, are designed to promote CD137 clustering by bridging T cells with HER2-positive tumor cells, thereby providing a selective activation signal to tumor-specific T cells. They are in development for immunotherapy of HER2-positive cancers.
To be presented today at a poster session during the 2015 Annual Meeting for the Society for Immunotherapy of Cancer (SITC), the data demonstrate that PRS-343 drug candidates drive tumor-targeted T cell activation on multiple HER2 high-expressing tumor cell lines but not on HER2 low-expressing tumor cell lines, confirming the requirement of tumor-expressed HER2 binding to trigger the CD137-mediated anti-tumor immune response. In contrast, a reference anti-CD137 monoclonal antibody was demonstrated to activate T cells independent of tumor cell HER2 expression.
In additional presented studies, the PRS-343 drug candidates exhibited desirable drug-like properties with respect to stability, pharmacokinetic, and immunogenicity profiles. These included retaining full activity after four weeks at 40°C, as well as having both a predicted serum half-life equivalent to a monoclonal antibody and low immunogenicity risk.
A copy of the poster can be viewed and downloaded by clicking
http://c.eqcdn.com/pierisag/files/posters/151102+November+Poster+postFinal+SITI.pdf.
Pieris Senior VP and Chief Development Officer, Louis Matis, M.D, commented, “CD137 is a highly promising target for cancer immunotherapy. However, conventional CD137-targeting antibodies lack tumor-selective activity, which may increase the risk of systemic toxicity. In contrast, by promoting CD137-induced immune activation that is localized to sites of HER2-positive tumor involvement, Pieris’ bispecifics have the potential to enhance the therapeutic window for the target, affording greater safety and efficacy. We are actively advancing this program toward clinical studies as a top priority.”
About Pieris Pharmaceuticals:
Pieris is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat severe asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin®, Anticalins® are registered trademarks of Pieris. For more information visit www.pieris.com.
SOURCE: Pieris Pharmaceuticals
Post Views: 218
